(−)-Pentazocine
SIGMA/P134 - ≥98% (HPLC)
CAS Number: 359-83-1
Empirical Formula (Hill Notation): C19H27NO
Molecular Weight: 285.42
EC Number: 206-634-6
MDL Number: MFCD00869259
Linear Formula: C19H27NO
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white |
| drug control | USDEA Schedule IV; Home Office Schedule 3; stupéfiant (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal) |
| form | solid |
| InChI | 1S/C19H27NO/c1-13(2)7-9-2 |
| InChI key | VOKSWYLNZZRQPF-CCKFTAQKSA |
| originator | Sanofi Aventis |
| Quality Level | 100 ![]() |
| SMILES string | C[C@@H]1[C@@H]2Cc3ccc(O)c |
| solubility | DMSO: >10 mg/mL |
| storage condition | protect from light |
| storage temp. | room temp |
| Biochem/physiol Actions: | Pentazocine is an analgesic with both agonist and antagonist activities. It acts as a κ- and σ-opioid receptor agonist and partial mu-receptor antagonist. Pentazocine pre-treatment reduces the frequency of fentanyl-induced cough and improves the anesthetic effect. |
| Features and Benefits: | This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P264 - P270 - P301 + P312 - P501 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 12352200 |


